Sling Therapeutics has closed a $123-million series C round as it advances linsitinib into Phase III testing for thyroid eye disease (TED), putting the oral small-molecule IGF-1R inhibitor on track to challenge infusion-based therapies including Amgen's Tepezza (teprotumumab-trbw) and Viridian Therapeutics' Lumvoa (veligrotug-vvze). The financing, led by Forbion with participation from TPG Life Sciences Innovations and new investor Sectoral Asset Management, comes as Sling begins dosing patient

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships Sept. 15, 2026 -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchest

Company's Cognitive Network Restoration Therapy (CNRT) technology aims to make meaningful cognitive recovery possible years after initial injury Targeting a brain hub involved in executive function, CNRT activates underperforming networks to reverse deficits and restore independence Groundbreaking therapeutic approach has the potential to transform chronic cognitive impairment care from rehabilitation to restoration Sept. 15, 2026 -- ReEmerge, Inc. (ReEmerge), a private MedTech company innovati

Shennon Biotechnologies has welcomed a new chief executive and refreshed its cash reserves, both of which will help shepherd the company's transition from early R&D to clinical development. The biotech on Monday raised $12 million and appointed Cyril Konto as CEO, succeeding founder Li Sun, who will transition to president and chief technology officer. Konto previously served as the executive director for early immuno-oncology clinical development at Pfizer, and prior to that, was the director

SBIR Phase II award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will support IND-enabling development of Vincere's USP30 inhibitor small molecule for acute kidney injury (AKI) Vincere's approach targets mitochondrial dysfunction and impaired mitophagy, key contributors to kidney injury and impaired recovery The award expands the clinical potential of Vincere's USP30 platform beyond Parkinson's disease and advances a second therapeutic molecule toward human s

Solstice Oncology has secured $225 million in series A funds to advance a next-gen immunotherapy that the biotech hopes will turn “darkness to light” for cancer care. The company licensed the Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, called porustobart, from China's Harbour BioMed back when Boston-based Solstice was founded in February. In return for a $105 million upfront package, Solstice can develop and commercialize the drug outside of China and has already

Financing led by the Angelini Lumira Biosciences Fund supports development of first-in-class medicines targeting neuronal hyperexcitability and expands Navion’s AI-enabled NaViGATion™ discovery platform Navion Neurosciences, Inc., a preclinical-stage biotechnology company developing next-generation, precision sodium channel therapeutics for neurological diseases, today announced the $10.8M first closing of a Seed financing, led by the Angelini Lumira Biosciences Fund with participation from 3B

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026 Financing led by RA Capital Management, joined by Canaan Partners, Forbion, and other investors Sept. 09, 2026 -- Solstice Oncology, a clinical-stage immuno-oncology company focused on treating c

Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective RNAi medicines targeting novel biology Dr. Stephen Djedjos appointed Senior Vice President, Clinical Development Moonwalk Biosciences , a biotechnology company developing first-in-class

Weight-loss giant Eli Lilly joined Moonwalk Biosciences' latest funding round, which will be used to advance the biotech's adipose tissue–directed siRNA therapy into first-in-human studies for obesity in late 2027. In addition to the US pharma, the financing saw participation from Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures. The oversubscribed $70-million series B was co-led by Alpha Wave Ventures and YK Bioventures. The round comes more than two and a half yea